ARTICLE | Finance
Joining the in(novation) crowd
Why Chinese biotechs BeiGene, Chi-Med are looking to NASDAQ
October 26, 2015 7:00 AM UTC
At least one buysider thinks the first two innovator Chinese biotechs to attempt a NASDAQ listing will be well-received by U.S. investors thanks to a combination of validating pharma deals and a stable of products against novel or hot cancer targets.
On Oct. 16, both BeiGene Ltd. and Hutchison China MediTech Ltd. (LSE:HCM) filed to raise up to $100 million on NASDAQ...